We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+10.42%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.14B
AUM Growth
+$26.3M
Cap. Flow
-$108M
Cap. Flow %
-5.04%
Top 10 Hldgs %
74.41%
Holding
40
New
1
Increased
15
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$21.1M
2
EPZM
Epizyme, Inc
EPZM
+$13.7M
3
ABMD
Abiomed Inc
ABMD
+$4M
4
AIMT
Aimmune Therapeutics
AIMT
+$2.22M
5
INSM icon
Insmed
INSM
+$1.5M

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$113M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$34.6M
3
SAGE
Sage Therapeutics
SAGE
+$4.98M
4
UTHR icon
United Therapeutics
UTHR
+$2M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.09M

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
$312M 14.55%
3,329,581
-565,382
-15% -$34.6M
ABMD
2
DELISTED
Abiomed Inc
ABMD
$280M 13.05%
1,951,284
+29,800
+2% +$4M
UTHR icon
3
United Therapeutics
UTHR
$22.6B
$242M 11.31%
1,867,315
-16,000
-0.8% -$2M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.9B
$217M 10.11%
2,384,719
+2,100
+0.1% +$191K
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$125M 5.86%
1,030,942
+3,882
+0.4% +$452K
INSM icon
6
Insmed
INSM
$28.7B
$96.5M 4.5%
5,621,816
+87,666
+2% +$1.5M
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$86M 4.02%
5,698,296
+907,245
+19% +$13.7M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$82.3M 3.84%
1,033,025
-68,926
-6% -$4.98M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$80M 3.73%
7,940,788
+57,800
+0.7% +$465K
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$73.6M 3.43%
2,676,393
+48,200
+2% +$1.36M
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$308M
$68.5M 3.2%
4,203,270
– –
AMAG
12
DELISTED
AMAG Pharmaceuticals
AMAG
$61.5M 2.87%
3,344,620
– –
PRTA icon
13
Prothena Corp
PRTA
$449M
$58.1M 2.71%
1,073,955
+18,100
+2% +$964K
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$4.9B
$45M 2.1%
1,613,330
+22,900
+1% +$682K
CELG
15
DELISTED
Celgene Corp
CELG
$38.3M 1.79%
295,240
– –
STAA icon
16
STAAR Surgical
STAA
$1.15B
$38.1M 1.78%
3,529,070
+55,900
+2% +$547K
ALGN icon
17
Align Technology
ALGN
$12.1B
$33.5M 1.56%
223,107
– –
KPTI icon
18
Karyopharm Therapeutics
KPTI
$44.2M
$31.4M 1.47%
231,172
+4,074
+2% +$603K
MNTA
19
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$30.2M 1.41%
1,787,576
+28,200
+2% +$429K
IMMU
20
DELISTED
Immunomedics Inc
IMMU
$26.6M 1.24%
+3,010,466
New +$21.1M
AIMT
21
DELISTED
Aimmune Therapeutics
AIMT
$26.5M 1.24%
1,289,719
+116,221
+10% +$2.22M
GILD icon
22
Gilead Sciences
GILD
$162B
$24.9M 1.16%
351,600
– –
SHPG
23
DELISTED
Shire pic
SHPG
$21.5M 1%
130,200
– –
EXAS
24
DELISTED
Exact Sciences
EXAS
$15.3M 0.72%
433,076
+7,800
+2% +$241K
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$733M
$10.5M 0.49%
385,502
-39,960
-9% -$1.09M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q2 2017 Portfolio in Review

As of Q2 2017, Palo Alto Investors held 40 positions worth $2.14B, up 1.2% from $2.12B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors withdrew a net $108M in Q2 2017, closing 2 positions and reducing 4 holdings. Its most notable exit was ZELTIQ Aesthetics, Inc., an estimated $113M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Immunomedics Inc worth $26.6M.

  • Palo Alto Investors's largest Q2 2017 buy was Immunomedics Inc: 3,010,466 shares worth $26.6M.
  • Palo Alto Investors added most to Epizyme, Inc in Q2 2017, an estimated $13.7M increase.
  • Palo Alto Investors's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $34.6M.
  • Palo Alto Investors fully exited ZELTIQ Aesthetics, Inc. in Q2 2017, selling an estimated $113M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $2.14B portfolio in Q2 2017.
  • Palo Alto Investors opened 1 new position and closed 2 in Q2 2017.
  • Palo Alto Investors's portfolio value rose 1.2% quarter-over-quarter to $2.14B.

Based on Palo Alto Investors's 13F filing for Q2 2017, filed 14 Aug 2017.